<?xml version="1.0" encoding="UTF-8"?><urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"><url><loc>https://mindmedicinelaw.com/briefing/psilocybin-and-treatment-resistant-depression-clinical-evidence-and-policy-outlo-20261118-59973</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18T15:06:36.783442+00:00</news:publication_date><news:title>Psilocybin and Treatment-Resistant Depression: Clinical Evidence and Policy Outlook</news:title><news:keywords>psilocybin, depression, treatment-resistant depression, clinical trials, FDA, psychedelic-assisted therapy, policy, anhedonia, mental health, drug development</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/optimi-health-advances-psychedelic-trials-phase-2b-revision-phase-3-plans-us-ind-20261118-59971</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18T15:06:13.861653+00:00</news:publication_date><news:title>Optimi Health Advances Psychedelic Trials: Phase 2b Revision, Phase 3 Plans, US IND Filings</news:title><news:keywords>optimi health, psychedelic clinical trials, phase 2b amendment, phase 3 planning, us ind filing, fda regulation, adaptive trial design, psychedelic therapeutics, regulatory pathways</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/ketamine-experience-intensity-and-antidepressant-outcomes-clinical-and-policy-im-20261118-59966</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18T15:06:00.178820+00:00</news:publication_date><news:title>Ketamine Experience Intensity and Antidepressant Outcomes: Clinical and Policy Implications</news:title><news:keywords>ketamine, psychedelic experience, antidepressant outcomes, clinical trial design, subjective experience, regulatory policy, insurance coverage, psychedelic-assisted therapy, treatment efficacy, mental health</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/self-transcendent-psychedelic-experiences-distinct-outcomes-in-clinical-research-20261117-60042</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18T22:07:30.518187+00:00</news:publication_date><news:title>Self-Transcendent Psychedelic Experiences: Distinct Outcomes in Clinical Research</news:title><news:keywords>self-transcendent experiences, psychedelic research, clinical trial design, mindset and intention, psilocybin, MDMA, cannabis, psychological outcomes, therapeutic protocols, risk factors</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/transformative-and-existential-strategies-in-trauma-therapy-insights-for-psyched-20261117-60044</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18T22:06:31.864226+00:00</news:publication_date><news:title>Transformative and Existential Strategies in Trauma Therapy: Insights for Psychedelic-Assisted Modalities</news:title><news:keywords>trauma therapy, psychedelic-assisted therapy, existential psychotherapy, group therapy, emdr, 3mdr, post-traumatic growth, meaning-making, clinical research, therapist training</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/rapid-acting-antidepressant-effects-of-anesthetic-drugs-clinical-evidence-and-tr-20261117-60077</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18T22:06:19.381984+00:00</news:publication_date><news:title>Rapid-Acting Antidepressant Effects of Anesthetic Drugs: Clinical Evidence and Translational Gaps</news:title><news:keywords>rapid-acting antidepressants, ketamine, esketamine, treatment-resistant depression, nitrous oxide, anesthetic drugs, mechanisms of action, clinical monitoring, translational research, regulatory policy</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/multidimensional-self-transcendence-in-psychedelic-therapy-clinical-and-research-20261117-60043</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18T22:06:07.145992+00:00</news:publication_date><news:title>Multidimensional Self-Transcendence in Psychedelic Therapy: Clinical and Research Implications</news:title><news:keywords>psychedelic therapy, self-transcendent experiences, clinical trial design, positive affect, mindset and intention, harm reduction, therapeutic protocols, ego dissolution, regulatory implications</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/ai-guided-precision-psychedelic-therapies-for-depression-in-taiwan-20261117-60061</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18T22:05:54.430789+00:00</news:publication_date><news:title>AI-Guided Precision Psychedelic Therapies for Depression in Taiwan</news:title><news:keywords>precision psychiatry, treatment-resistant depression, taiwan, ai in mental health, psychedelic therapy, neuroimaging biomarkers, clinical staging, technology transfer, international collaboration</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/ketamine-for-treatment-resistant-depression-clinical-practice-and-policy-in-the--20261117-59972</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18T15:06:49.236588+00:00</news:publication_date><news:title>Ketamine for Treatment-Resistant Depression: Clinical Practice and Policy in the US</news:title><news:keywords>ketamine, treatment-resistant depression, TRD, off-label use, clinical guidance, FDA, esketamine, psychiatric clinics, policy, safety</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/oregon-psilocybin-home-services-case-legal-boundaries-and-implications-20261117-59974</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18T15:06:24.628648+00:00</news:publication_date><news:title>Oregon Psilocybin Home Services Case: Legal Boundaries and Implications</news:title><news:keywords>oregon psilocybin law, home-based facilitation, psychedelic regulation, legal precedent, measure 109, oregon health authority, psilocybin access, service delivery models, policy implications</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/meta-analysis-context-and-method-shape-psilocybin-critical-period-findings-20261116-60065</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18T22:06:56.022066+00:00</news:publication_date><news:title>Meta-Analysis: Context and Method Shape Psilocybin Critical Period Findings</news:title><news:keywords>psilocybin, critical period reopening, context dependence, social reward learning, preclinical research, meta-analysis, clinical trial design, set and setting, methodological rigor, psychedelic neuroscience</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/ketamine-trials-and-depression-rethinking-evidence-standards-20261116-60079</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18T22:06:43.749928+00:00</news:publication_date><news:title>Ketamine Trials and Depression: Rethinking Evidence Standards</news:title><news:keywords>ketamine, depression, clinical trials, treatment-resistant depression, patient selection, outcome measures, trial design, psychiatry, evidence-based medicine, risk-benefit</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/psilocybin-alters-neuronal-activity-in-mice-acute-and-lasting-effects-20261116-60064</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18T22:05:40.634588+00:00</news:publication_date><news:title>Psilocybin Alters Neuronal Activity in Mice: Acute and Lasting Effects</news:title><news:keywords>psilocybin, neuroplasticity, neuronal firing, mouse brain, neuropixels probes, psychiatric research, clinical trial design, persistent effects, regulatory policy</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/mglu2-antagonists-enhance-scopolamine-s-antidepressant-effects-implications-for--20261116-59815</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17T22:06:34.293859+00:00</news:publication_date><news:title>mGlu2 Antagonists Enhance Scopolamine's Antidepressant Effects: Implications for Depression Therapeutics</news:title><news:keywords>mglu2 antagonists, scopolamine, rapid-acting antidepressants, glutamatergic modulation, depression treatment, cognitive side effects, clinical trial design, neuropharmacology, bdnf-trkb signaling</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/shared-depression-circuit-mapped-implications-for-psychedelic-trials-20261115-59816</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17T22:06:51.928946+00:00</news:publication_date><news:title>Shared Depression Circuit Mapped: Implications for Psychedelic Trials</news:title><news:keywords>depression circuit, gray matter volume, major depressive disorder, psychedelic trials, rTMS response, patient stratification, biomarkers, clinical trial design, neuromodulation, precision psychiatry</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/iv-ketamine-for-trd-evidence-and-policy-in-resource-limited-settings-20261114-60083</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18T22:07:07.461029+00:00</news:publication_date><news:title>IV Ketamine for TRD: Evidence and Policy in Resource-Limited Settings</news:title><news:keywords>iv ketamine, treatment-resistant depression, resource-limited settings, public health policy, generic drugs, hospital procurement, clinical efficacy, esketamine, psychiatric treatment, implementation challenges</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/beta-oscillations-as-a-target-in-psychosis-implications-for-psychedelic-research-20261110-59665</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17T15:05:14.704824+00:00</news:publication_date><news:title>Beta Oscillations as a Target in Psychosis: Implications for Psychedelic Research</news:title><news:keywords>beta oscillations, psychosis, predictive processing, schizophrenia, psychedelic research, cortical oscillations, clinical trial design, biomarkers, neurofeedback, precision psychiatry</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/psychedelic-metaplasticity-mechanisms-and-persistence-limits-20261108-60058</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18T22:07:19.879154+00:00</news:publication_date><news:title>Psychedelic Metaplasticity: Mechanisms and Persistence Limits</news:title><news:keywords>psychedelic metaplasticity, 5-HT2A receptor, epigenomic priming, histone acetylation, persistent effects, clinical translation, mechanistic research, regulatory science</news:keywords></news:news></url></urlset>